Jan 30, 2020 8:30 am EST Emerald Bioscience to Present at the 9th Annual Glaucoma 360 New Horizons Forum and BIO CEO & Investor Forum
Jan 13, 2020 8:30 am EST Emerald Bioscience Provides Update on Recent Progress and Expected 2020 Milestones
Dec 10, 2019 8:30 am EST Emerald Bioscience Inc. Announces Cannabidiol-Valine-Hemisuccinate Possesses Enhanced Anti-Seizure Activity when Compared with Cannabidiol (CBD) in the StemoniX Human Neural Tissue Platform
Dec 9, 2019 8:30 am EST Emerald Bioscience Reports its Proprietary Analog of Cannabidiol, Cannabidiol-Valine-Hemisuccinate (CBDVHS), Exhibits Greater Potency and Antifibrotic Activity than Cannabidiol (CBD) in Biomarker Studies in Human Ocular Donor Tissues
Oct 30, 2019 8:30 am EDT Emerald Bioscience to Present Research Data Related to its Glaucoma Drug Candidate, NB1111, at 2019 American Association of Pharmaceutical Scientists
Oct 15, 2019 8:35 am EDT Emerald Bioscience’s NB1111 Demonstrates Superiority in Lowering Intraocular Pressure Compared to Global Standard of Care Glaucoma Treatment in Preclinical Model